81
Participants
Start Date
January 6, 2014
Primary Completion Date
October 16, 2019
Study Completion Date
April 1, 2021
Interleukin 2
Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
Médecine interne - Hôpital Saint-Antoine, Paris
Service d' Hépato Gastro Entérologie - Hôpital SAINT-ANTOINE, Paris
Service de Gastro Entérologie - Hôpital SAINT-ANTOINE, Paris
Service de Rhumatologie - Hôpital SAINT-ANTOINE, Paris
CIC - Hôpital PITIE SALPETRIERE, Paris
Service de Médecine Interne - Hôpital PITIE SALPETRIERE, Paris
Service de Rhumatologie - Hôpital PITIE SALPETRIERE, Paris
Service de Dermatologie - Hôpital COCHIN, Paris
Service de médecine vasculaire - HEGP, Paris
Henri Mondor - Médecine Interne, Créteil
Centre Hépato-Biliaire - Hôpital Paul Brousse, Villejuif
Collaborators (1)
Iltoo Pharma
INDUSTRY
Assistance Publique - Hôpitaux de Paris
OTHER